1 reports of this reaction
11.1% of all MAGNESIUM SULFATE, UNSPECIFIED FORM reports
#5 most reported adverse reaction
MYALGIA is the #5 most commonly reported adverse reaction for MAGNESIUM SULFATE, UNSPECIFIED FORM, manufactured by ANI Pharmaceuticals, Inc.. There are 1 FDA adverse event reports linking MAGNESIUM SULFATE, UNSPECIFIED FORM to MYALGIA. This represents approximately 11.1% of all 9 adverse event reports for this drug.
Patients taking MAGNESIUM SULFATE, UNSPECIFIED FORM who experience myalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYALGIA is a frequently reported adverse event for MAGNESIUM SULFATE, UNSPECIFIED FORM, accounting for a significant proportion of all reports.
In addition to myalgia, the following adverse reactions have been reported for MAGNESIUM SULFATE, UNSPECIFIED FORM:
The following drugs have also been linked to myalgia in FDA adverse event reports:
MYALGIA has been reported as an adverse event in 1 FDA reports for MAGNESIUM SULFATE, UNSPECIFIED FORM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYALGIA accounts for approximately 11.1% of all adverse event reports for MAGNESIUM SULFATE, UNSPECIFIED FORM, making it a notable side effect.
If you experience myalgia while taking MAGNESIUM SULFATE, UNSPECIFIED FORM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.